US › Healthcare

Arcturus Therapeutics Holdings Inc (ARCT)

US · Healthcare · Biotechnology

$6.22+3.67%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$610,000
Revenue YoY
-97.9%
Net profit
$-27.0M
Profit YoY
-91.6%
EPS
$-0.95
EPS estimate
$-1.01
Net margin
-4,420.3%

EPS came in at -0.95 against a street estimate of -1.01 — a beat of 6.2%.

Key statistics

Market cap
$163.7M
Forward P/E
2.5
P/B
0.86
Book value
$6.73
EPS (TTM)
$-2.83
52-week high
$24.17
52-week low
$5.50
50-day MA
$6.87
200-day MA
$7.90
Beta
2.27

Analyst view

Analysts rate Arcturus Therapeutics Holdings Inc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $20.60.

Shareholding

Insiders
7.99%
Institutions
80.57%

Largest institutional holders

FundStake
Federated Hermes Inc11.62%
ARK Investment Management LLC9.74%
BlackRock Inc9.19%
Amova Asset Management Americas, Inc8.05%
Sumitomo Mitsui Trust Group Inc8.05%
Vanguard Capital Management, LLC3.89%
Two Sigma Investments LLC3.81%
Vanguard Portfolio Management, LLC3.44%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Arcturus Therapeutics Holdings Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.